Table 2.
Baseline clinical characteristics and medication use on hospital discharge among patients who presented for RFU visit, stratified by ReDS use vs. no ReDS use
| Overall (n = 220) | ReDS (n = 80) | No ReDS (n = 140) | P‐value | |
|---|---|---|---|---|
| Clinical characteristics | ||||
| Age, years | 62.9 ± 14.7 | 65.2 ± 13.2 | 61.5 ± 15.4 | 0.08 |
| Male sex | 139 (63.2%) | 53 (66.3%) | 86 (61.4%) | 0.48 |
| Body mass index, kg/m2 | 28.8 ± 7.0 | 27.3 ± 5.1 | 29.7 ± 7.7 | 0.02 |
| White race | 46 (20.9%) | 17 (21.3%) | 29 (20.7%) | 0.93 |
| Arterial hypertension | 156 (72.2%) | 60 (75.0%) | 96 (70.6%) | 0.49 |
| Diabetes mellitus | 90 (41.7%) | 33 (41.3%) | 57 (41.9%) | 0.92 |
| Renal insufficiency | 49 (61.3%) | 49 (61.3%) | 77 (55.0%) | 0.37 |
| Chronic obstructive pulmonary disease | 77 (35.0%) | 28 (35.0%) | 49 (35.0%) | 1.00 |
| Atrial fibrillation | 90 (40.9%) | 28 (35.0%) | 62 (44.3%) | 0.18 |
| Coronary artery disease | 112 (52.1%) | 44 (55.0%) | 68 (50.4%) | 0.51 |
| Smoking status | 0.38 | |||
| Never smoker | 86 (43.2%) | 32 (43.2%) | 54 (43.2%) | |
| Current smoker | 22 (11.1%) | 11 (14.9%) | 11 (8.8%) | |
| Former smoker | 91 (45.7%) | 31 (41.9%) | 60 (48.0%) | |
| New York Heart Association class | 0.35 | |||
| I | 1 (0.5%) | 0 (0.0%) | 1 (0.8%) | |
| II | 53 (26.1%) | 19 (25.7%) | 34 (26.4%) | |
| III | 126 (62.1%) | 50 (67.6%) | 76 (58.9%) | |
| IV | 23 (11.3%) | 5 (6.8%) | 18 (14.0%) | |
| Left ventricular ejection fraction < 40% | 143 (66.2%) | 56 (70.9%) | 87 (63.5%) | 0.27 |
| Number of prior hospitalizations | 2.1 ± 1.9 | 2.0 ± 1.7 | 2.2 ± 2.1 | 0.41 |
| Brain natriuretic peptide, pg/mL | 917.2 ± 1083.3 | 979.4 ± 1300 | 881.0 ± 937.9 | 0.52 |
| Medications at hospital discharge | ||||
| ARNIs | 35 (15.9%) | 12 (15.0%) | 23 (16.4%) | 0.78 |
| ACE inhibitors or ARBs | 109 (49.6%) | 44 (55.0%) | 65 (46.4%) | 0.22 |
| Mineralocorticoid receptor antagonists | 92 (41.8%) | 37 (46.3%) | 55 (39.3%) | 0.31 |
| Beta‐blockers | 185 (84.1%) | 67 (83.8%) | 118 (84.3%) | 0.92 |
| Calcium channel blockers | 17 (7.7%) | 9 (11.3%) | 8 (5.7%) | 0.14 |
| Loop diuretics | 190 (86.4%) | 69 (86.3%) | 121 (86.4%) | 0.97 |
| Thiazide diuretics | 12 (5.5%) | 3 (3.8%) | 9 (6.4%) | 0.40 |
| Inotropes | 14 (6.4%) | 2 (2.5%) | 12 (8.6%) | 0.08 |
ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker; ARNIs, angiotensin receptor‐neprilysin inhibitors; ReDS, remote dielectric sensing.
Results are reported as n (%) or mean ± standard deviations.